Eli Lilly Is Acquiring Merdia Biosciences for Up to $2.88 Billion. Here's What That Means for Investors.
Hardly for the first time recently, the company is making a pricey acquisition.
Overview
Eli Lilly (NYSE:LLY) announced yet another acquisition on Monday. The American pharmaceutical giant has signed a deal to acquire privately held, clinical-stage biotech Merida for nearly $3 billion.
That's a lot of scratch, even for a powerhouse operator like Lilly. Here's what shareholders and other Lilly watchers need to know about the company's new asset-to-be.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.